Work

Phase II trial of 10-day ASTX727 (decitabine/cedazuridine) in combination with venetoclax for relapsed or refractory acute myeloid leukemia.

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.6551

Authors: Mehmet Uyanik, Courtney Denton Dinardo, Maro Ohanian, Kelly Sharon Chien, Yesid Alvarado Valero, Gautam Borthakur, Naval Guastad Daver, Ghayas C. Issa, Elias Jabbour, Lucia Masarova, Koichi Takahashi, William G. Wierda, Corey Alexander Bradley, Allison Pike, Duyen H Nguyen, Farhad Ravandi-Kashani, Guillermo Garcia-Manero, Marina Konopleva, Abhishek Maiti

Institutions: The University of Texas MD Anderson Cancer Center, Albert Einstein College of Medicine, Montefiore Medical Center, Montefiore Einstein Comprehensive Cancer Center

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: University of Texas MD Anderson Cancer Center

OpenAlex ID: W4410809211

Cites:

Cited by:

Related to: 10